Agile - Top 15 Biotech VC Deals of 2010

Company: Agile Therapeutics
Based: Princeton, NJ
Amount: $45M

Investors: Investor Growth Capital, Care Capital, ProQuest Investments, Kaiser Permanente Ventures and Novitas Capital

Scoop: After a three-year dry spell, Agile Therapeutics entered the VC fray with a $45 million Series B preferred stock financing with three new investing firms. "The general conditions of the market don't help any company raise money, and we're one of the few that's done a significant raise from external investors," former Agile CEO Thomas Rossi told FierceBiotech at the time.

Agile is using the funding to finish a Phase III clinical trial of its weekly contraceptive patch AG200-15, a potential competitor to the market's only approved contraceptive patch, Johnson & Johnson's Ortho Evra. The company finished enrollment for its Phase III trial in October.

Agile - Top 15 Biotech VC Deals of 2010
Read more on

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.